写在文章前的声明：在本文之前的说明：本文中所列的投资信息，只是一个对基金资产净值进行排行的客观描述，并无主观倾向性，也不是投资建议，纯属 娱乐性质。 | 排名 | 代码 | 基金简称 | 2025-08-20 | | 2025-08-19 | | 理业量 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 車位净值3 | 累计净值8 | 車位净值8 | 累计净值3 | | | 1 | 017744 | 嘉实绿色主题股票发起式A | 1.1888 | 1.1888 | 1.1232 | 1.1232 | 0.06 | | 2 | 017745 | 嘉实绿色主题股票发起式C | 1.1712 | 1.1712 | 1.1066 | 1.1066 | 0.06 | | 3 | 162214 | 宏利领先中小盘混合 | 0.9990 | 0.9990 | 0.9500 | 0.9500 | 0.04 | | 4 | 021492 | 中航远见领航混合发起C | 1.3618 | 1.4418 | 1.2951 | 1.3751 | 0.06 | | ...

Core Viewpoint - The market has seen significant recovery, with the Shanghai Composite Index breaking the previous high from September 2022, indicating a bullish trend in the equity market [1][6]. Group 1: Market Performance - As of August 13, 2023, 160 funds have doubled in value since the September 2022 peak, with 12 funds achieving this milestone in 2023 alone [1][6]. - The "Wande Equity Mixed Fund Index" has risen by 19.67% this year, and since the September 2022 rally, it has increased by 43.18% [6][8]. - The Hang Seng Innovation Drug Index has surged by 109% this year, while the Wande Innovation Drug Index has increased by 51% [13]. Group 2: Fund Recovery and Redemption - Research indicates that the average return of new funds launched between 2019 and 2021 has returned to break-even, while existing funds from the previous bull market show an average loss of 5% [8][9]. - Despite the recovery, there is significant redemption pressure on equity funds, with a 56.43% increase in net redemptions for active equity funds in Q2 2025 [10]. - Investors are showing a tendency to redeem funds once they reach break-even, reflecting a lack of confidence in long-term returns [10][11]. Group 3: Sector Focus and Fund Management - Funds heavily invested in innovative sectors such as pharmaceuticals, AI, and robotics have generally maintained their positions, with few making significant adjustments [1][12]. - The majority of funds focused on innovation sectors have not reduced their holdings, despite some individual fund managers considering adjustments due to high valuations [13][14]. - There is a notable trend of funds shifting towards fixed-income products, with 50% to 70% of monthly sales in certain banks being allocated to these products [1][11].

【导读】QDII基金限购不断加码 今年6月底，多家合格境内机构投资者获批新的QDII额度，不少QDII基金一度恢复正常申购业务或提升申购限制金额。 不过，近期QDII基金限购再现加码之势，多只基金降低大额申购限额，最低降至500元。 就在一周前，该基金刚公告，自8月7日起将大额申购限额调整为2000元，而在7月初时，这一门槛刚调整到10000元。 无独有偶。同日，华宝基金旗下华宝纳斯达克精选股票（QDII）、华宝标普美国品质消费股票指数基金（LOF）、华宝标普石油天然气上游股票指数 （LOF）也发布调整大额申购金额上限的公告，最新限额在500元—1000元不等。 跟华宝海外科技股票（QDII-LOF）一样，上述基金自7月初以来也多次调整限购门槛，自10000元—20000元限额水平持续下调。 | 基金名称 | | 华宝海外科技股票型证券投资基金(QDII-LOF) | | --- | --- | --- | | 基金简称 | | 华宝海外科技股票(QDII-LOF) | | 基金主代码 | | 501312 | | 基金管理人名称 | | 华宝基金管理有限公司 | | 公告依据 | | 《华宝海外科技股票型证 ...

Core Viewpoint - The recent trend shows an increase in restrictions on QDII funds, with many funds lowering their large subscription limits to as low as 500 yuan, indicating a tightening of investment access despite previously approved new quotas [2][3][5]. Summary by Sections QDII Fund Subscription Limits - Several QDII funds have recently reduced their large subscription limits, with the minimum now set at 500 yuan [3][8]. - On August 13, the Hua Bao Overseas Technology Stock (QDII-LOF) announced a new limit of 1,000 yuan for single-day subscriptions, down from 2,000 yuan just a week prior [5][8]. - Other funds, including Hua Bao Nasdaq Select Stock (QDII) and Hua Bao S&P US Quality Consumption Stock Index Fund (LOF), have also adjusted their limits to between 500 and 1,000 yuan [8][10]. Performance of QDII Funds - QDII funds have shown strong performance this year, with many funds reporting positive unit net value growth rates. For instance, the Hui Tian Fu Hong Kong Advantage Selection (QDII) has a growth rate exceeding 135%, leading the market [11][12]. - The overall market sentiment is improving, with expectations of more certainty in global markets as risks are gradually released [12]. Market Trends and Future Outlook - The tightening of subscription limits may be a response to the influx of capital attracted by the strong performance of QDII funds [12]. - There is a potential shift in global capital allocation, with investors possibly reducing their exposure to US stocks in favor of high-quality non-US assets due to rising uncertainties in the US political and economic landscape [12].

Group 1 - In July 2023, 670 comparable QDII funds were analyzed, with 586 funds (87.46%) showing an increase in net value, while 80 funds experienced a decline, and 4 funds remained flat [1] - 15 QDII funds had a monthly increase exceeding 24%, with the top performers being E Fund Global Healthcare Mixed Fund (QDII) C (USD) at 28.94%, followed closely by other E Fund variants [1] - The E Fund Global Healthcare Mixed Fund (QDII) C (USD) was established on November 15, 2023, while its A share (USD) was launched on January 20, 2020 [1] Group 2 - As of July 31, 2025, the year-to-date returns for the top E Fund variants were 97.18%, 96.71%, 96.05%, and 95.63%, with cumulative net values ranging from 0.1956 to 1.4089 [2] - The fund maintained a positive outlook on the Chinese pharmaceutical industry, particularly focusing on innovative drug companies, and optimized stock selection as of the second quarter [2] - The largest fund by size among the top performers was the GF CSI Hong Kong Innovative Drug ETF, with a scale of 15.9 billion yuan and a July increase of 27.04% [2] Group 3 - The Manulife India Equity Fund (QDII), established on January 30, 2019, reported a year-to-date return of -2.38% and a cumulative net value of 1.5203 yuan as of July 31, 2025 [3] - The fund's investment strategy shifted from strong defensive positions to include more mid-cap companies and sectors like public utilities and new consumption [3] - The top ten holdings of the Manulife India Equity Fund included major companies such as Reliance Industries and HDFC Bank as of the second quarter [3]

Group 1 - The core viewpoint of the news is that multiple QDII funds, including the Bosera Nasdaq 100 ETF, are implementing subscription restrictions to protect the interests of existing fund holders and manage net asset value volatility [1][2][3] - As of August 3, 41 out of 676 QDII funds are in a suspended subscription state, and 349 funds have restricted large subscriptions, indicating that 57.69% of QDII funds are subject to some form of subscription limitation [3][4] - Several QDII funds have reported significant performance gains, with some achieving over 90% returns year-to-date, which has led to increased inflows and subsequent subscription restrictions [4][5] Group 2 - The recent approval of new QDII investment quotas aims to meet the reasonable demand for overseas investments, with 60 fund managers and securities firms receiving a total of $21.2 billion in new quotas [5] - Industry experts suggest that the strong performance of QDII funds focused on Hong Kong stocks and innovative pharmaceuticals reflects investor preference for valuation recovery and growth opportunities [5] - Future investment opportunities may arise from global technology leaders and high-quality assets in emerging markets, as well as the overseas expansion of competitive Chinese enterprises [5]

Group 1 - As of July 31, 12 public funds have achieved a net value growth rate exceeding 100% in 2023, primarily focusing on themes such as innovative drugs, biomedicine, and healthcare, closely linked to the strong performance of the Hong Kong innovative drug sector [1][2] - The top-performing fund, Huatai-PB Hong Kong Advantage Selection A, boasts a 143.24% year-to-date net value growth rate, heavily invested in Hong Kong innovative drugs, with its top ten holdings all being Hong Kong innovative drug stocks [2][3] - Other notable funds with over 100% growth include Changcheng Medical Industry Selection A and Bank of China Hong Kong Stock Connect Medical A, along with several ETFs focused on innovative drugs [2][3] Group 2 - The strong performance of the Hong Kong innovative drug sector is driven by three main factors: increased collaboration needs due to multinational pharmaceutical companies facing "patent cliffs," many biotech companies approaching breakeven within three to five years, and comprehensive policy support from research to payment [3] - The manager of Huatai-PB Hong Kong Stock Connect Innovative Drug ETF noted a significant acceleration in Chinese innovative drug companies' overseas expansion since 2025, with multiple large overseas licensing deals indicating global recognition of China's innovation capabilities [3] - The manager of Huatai-PB Hong Kong Advantage Selection Mixed Fund emphasized that with the recovery of market risk appetite, innovative drug companies with core competitiveness will demonstrate long-term growth value, focusing on globally competitive innovative drug firms and high-quality medical device leaders [3] Group 3 - The Hong Kong stock market has seen significant liquidity improvement and increased trading activity in 2023, enhancing its resilience and attracting global capital to quality assets [4] - The Hang Seng Index has outperformed major global markets with over a 20% increase in the first half of the year, and net inflows from southbound funds exceeded 700 billion yuan, marking a record high [4] - Looking ahead, the Hong Kong market is expected to continue its diversification trend, supported by improving free cash flow and increasing share buybacks among listed companies, which may lay a solid foundation for long-term stable performance [4]

Group 1 - As of July 31, 12 public funds have achieved a net value growth rate exceeding 100% in 2023, primarily focusing on themes such as innovative drugs, biomedicine, and healthcare, closely linked to the strong performance of the Hong Kong innovative drug sector [1][2] - The top-performing fund, Huatai-PB Hong Kong Advantage Selection A, has a net value growth rate of 143.24%, heavily invested in Hong Kong innovative drugs, with its top ten holdings all being Hong Kong innovative drug stocks [2][3] - Other funds, including Changcheng Medical Industry Selection A and Bank of China Hong Kong Stock Connect Medicine A, also reported net value growth rates over 100%, indicating a robust performance across various funds in the innovative drug sector [2][3] Group 2 - The strong performance of the Hong Kong innovative drug sector is driven by three main factors: increased collaboration demand due to multinational pharmaceutical companies facing "patent cliffs," many biotech companies approaching breakeven within three to five years, and comprehensive policy support from R&D to payment [3] - The manager of Huatai-PB Hong Kong Stock Connect Innovative Drug ETF noted a significant acceleration in Chinese innovative drug companies' overseas expansion since 2025, with multiple large overseas licensing deals indicating global recognition of China's innovation capabilities [3] - The manager of Huatai-PB Hong Kong Advantage Selection Mixed Fund emphasized that with the recovery of market risk appetite, innovative drug companies with core competitiveness will demonstrate long-term growth value, focusing on globally competitive innovative drug firms and high-quality medical device leaders [3] Group 3 - The Hong Kong stock market has seen significant liquidity improvement and increased trading activity, enhancing its resilience and overall performance, with the Hang Seng Index rising over 20% this year, outperforming major global markets [4] - The net inflow of over 700 billion yuan from southbound funds has set a new high for the same period, indicating a strong demand for quality assets in the Hong Kong market [4] - Looking ahead, the Hong Kong market is expected to continue its diversification trend, supported by ongoing policy measures, improved free cash flow among listed companies, and an increasing buyback scale, which reflects enhanced corporate quality and shareholder return awareness [4][5]

Group 1 - The performance of actively managed equity funds has significantly improved this year, with over 90% achieving positive returns and a notable emergence of "doubling funds" [1][2] - As of July 28, the average return of actively managed equity funds is 13.74%, with nearly 400 funds exceeding 30% returns and around 60 funds surpassing 60% [1] - Several funds have reported returns exceeding 100%, including the Changcheng Medical Industry Selected Mixed Fund at 120.89% and the Huatai-PB Hang Seng Innovation Drug ETF [1][2] Group 2 - Funds heavily invested in the innovative drug sector have shown strong performance, with the sector continuing to rise as of July 29, indicating potential for more "doubling funds" [2] - Other sectors such as technology and new consumption are also performing well, with funds like the GF Growth Leading Mixed Fund achieving a return of 90.5% [2] - The risk appetite of private equity and financing funds has played a crucial role in driving market uptrends since June 23, contributing to a structural market rally [2] Group 3 - The market recovery has sparked enthusiasm among fund companies, with 48 equity funds currently in issuance and 39 more set to launch soon [3] - Public funds have increased their stock positions significantly, with the average allocation for equity mixed funds rising to approximately 85.99% as of July 25, up by 2.05 percentage points from July 18 [3]

Group 1 - The core viewpoint of the report indicates that the construction materials and coal industries performed well during the period, with the Shanghai Composite Index rising by 1.67% and the Shenzhen Component Index increasing by 2.33% [2][9] - In the recent 12 periods, the comprehensive and pharmaceutical industries showed strong performance, suggesting potential investment opportunities in these sectors [9] - Active equity funds focusing on electronics and coal industries also demonstrated superior performance during this period [14] Group 2 - Among various fund types, actively managed stock funds increased by 1.55%, while mixed funds rose by 1.63%, and bond funds saw a slight decline of 0.16% [2] - The average return of convertible bond funds was notably high at 12.46% year-to-date, indicating a strong performance in this category [17] - QDII funds, particularly those focused on Asia-Pacific and emerging markets, led the performance with an increase of 2.56% during the period [19][21]